Vedere Bio is committed to innovating therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) using an optogenetics-based platform that is mutation-agnostic, allowing treatment development unbounded by specific genetic causes
Vedere Bio is committed to innovating therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) using an optogenetics-based platform that is mutation-agnostic, allowing treatment development unbounded by specific genetic causes. Their proprietary adeno-associated virus (AAV) vectors enable scalable, office-based treatments for visually impaired patients.